Developments Findings identify Propanc’s PRP as potential strategy to reprogram chemo-resistant pancreatic cancer Propanc Biopharma (NASDAQ: PPCB) has announced new preclinical research from an academic–industry collaboration from the Universities of Jaén and Granada, led by Dr. Maria Belén Toledo, that has identified the company’s... October 16, 2026